Search

Abstract: In the last decades, the potential association between antidepressants and cancer risk has been increasingly investigated. Fundamental researches, performed on animal models and cell tumoral lines, have highlighted several biological mechanisms possibly supporting this association. Nevertheless, the epidemiological studies investigating the risk of cancer in patients receiving selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) have provided conflicting and inconclusive results. Therefore, the prescription of several antidepressants in oncologic patients still remains a matter of discussion. The aim of this review is to present and discuss available evidence concerning the association between the risk of breast and prostate cancer and the use of antidepressant medications. Thus, consistencies, differences, and contradictions of available data are reported. A special focus is addressed to amisulpiride, a widely prescribed drug still poorly investigated with regard to the risk of cancer occurrence and recurrence. Overall, there is no definitive evidence of increased risk of breast and prostate cancer among patients exposed to SSRIs and TCAs. The association between amisulpiride and cancer risk has been to date scarcely explored and considered in clinical settings. Nevertheless, the hyperprolactinemia frequently resulting from its adoption has been repeatedly associated, to increased cancer risk and poorer prognosis in cancer patients. Thus, the use of amisulpiride among cancer patients should be carefully considered. [Copyright &y& Elsevier]

Abstract: We report an experimental and theoretical study on the properties of the aniline–water and aniline–methanol jet cooled complexes. In both complexes the ligand (H2O or CH3OH) is hydrogen bonded to aniline, the interaction taking place at the lone pair of the nitrogen, in the amino group. The S1 ←S0 electronic excitation spectrum in both cases exhibits a very broad and weak band, blue shifted with respect to the origin band of aniline by ≈700cm−1. Ab initio calculations, at different levels of theory with the cc-pvdz electronic basis set, were performed on aniline–water and predict a strong binding energy decrease in the excited state and a large change in geometry, in agreement with experimental results. [Copyright &y& Elsevier]

• Robotic rehabilitation should be combined with neuromodulatory intervention. • Serotonin may support stroke recovery by inducing cortical disinhibition. • Combined treatment promoted recovery in general motor tests and manual dexterity. Despite recent progresses in robotic rehabilitation technologies, their efficacy for post-stroke motor recovery is still limited. Such limitations might stem from the insufficient enhancement of plasticity mechanisms, crucial for functional recovery. Here, we designed a clinically relevant strategy that combines robotic rehabilitation with chemogenetic stimulation of serotonin release to boost plasticity. These two approaches acted synergistically to enhance post-stroke motor performance. Indeed, mice treated with our combined therapy showed substantial functional gains that persisted beyond the treatment period and generalized to non-trained tasks. Motor recovery was associated with a reduction in electrophysiological and neuroanatomical markers of GABAergic neurotransmission, suggesting disinhibition in perilesional areas. To unveil the translational potentialities of our approach, we specifically targeted the serotonin 1A receptor by delivering Buspirone, a clinically approved drug, in stroke mice undergoing robotic rehabilitation. Administration of Buspirone restored motor impairments similarly to what observed with chemogenetic stimulation, showing the immediate translational potential of this combined approach to significantly improve motor recovery after stroke. [ABSTRACT FROM AUTHOR]